Financial Performance - Operating revenue for the first nine months of 2024 was ¥84.21 million, down 17.91% from ¥102.59 million in the same period of 2023[4] - Net profit attributable to shareholders for the first nine months of 2024 was ¥8.18 million, a decline of 46.68% from ¥15.33 million year-on-year[4] - Basic earnings per share for the first nine months of 2024 decreased by 55.81% to ¥0.19 from ¥0.43 in the same period of 2023[4] - The company reported a net profit of ¥4.29 million for the third quarter of 2024, a slight increase of 0.24% compared to ¥4.28 million in the same quarter of 2023[4] - The weighted average return on equity based on net profit attributable to shareholders was 4.05% for the first nine months of 2024, down from 10.91% in the same period of 2023[4] - Net profit decreased by 46.68% to 8,175,893.45, attributed to a 17.91% decline in operating revenue[6] - The net profit for the current period is 9,870,912.86, a decrease from 16,796,588.11 in the same period last year, representing a decline of approximately 41.5%[29] - Operating revenue for the current period is 83,879,143.45, compared to 102,175,941.74 in the same period last year, indicating a decrease of about 17.8%[29] - Operating profit stands at 11,243,730.42, down from 19,192,333.75, reflecting a decline of approximately 41.6%[29] - The total comprehensive income for the current period is 9,870,912.86, down from 16,796,588.11, indicating a decline of approximately 41.5%[30] Cash Flow and Liquidity - Cash flow from operating activities for the first nine months of 2024 was negative at ¥7.78 million, worsening by 9.40% compared to negative ¥7.11 million in the previous year[4] - Cash inflow from operating activities for the first nine months of 2024 was CNY 66,736,058.89, a decrease of 21.8% compared to CNY 85,346,165.75 in the same period of 2023[31] - Cash outflow from operating activities totaled CNY 74,512,796.57, down 19.5% from CNY 92,454,464.95 year-on-year[32] - Net cash flow from operating activities was negative CNY 7,776,737.68, worsening from negative CNY 7,108,299.20 in the previous year[32] - Cash inflow from investment activities reached CNY 187,820,662.64, significantly up from CNY 70,751,317.42 in the same period last year, marking a 165.5% increase[32] - Cash outflow from investment activities surged to CNY 260,258,529.72, compared to CNY 127,531,377.33 in the previous year, reflecting a 104.5% increase[32] - Net cash flow from investment activities was negative CNY 72,437,867.08, compared to negative CNY 56,780,059.91 in the same period last year[33] - Cash inflow from financing activities was CNY 72,666,488.41, with no comparable figure from the previous year[33] - Cash outflow from financing activities was CNY 9,265,674.95, a significant decrease from CNY 440,331.02 year-on-year[33] - The ending cash and cash equivalents balance was CNY 18,328,938.78, down from CNY 86,743,160.48 at the end of the previous year[33] - The company reported a net decrease in cash and cash equivalents of CNY 88,475,981.80, contrasting with an increase of CNY 10,048,810.72 in the same period last year[33] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥257.71 million, a decrease of 3.54% compared to ¥267.18 million at the end of 2023[3] - The company's cash and cash equivalents decreased by 82.89% to ¥18.48 million, primarily due to cash management products not yet matured and increased engineering investments[5] - Accounts receivable increased significantly by 542.65% to ¥22.14 million, attributed to the timing of dealer repayments[5] - The construction in progress increased significantly by 11,793.20% to ¥19.33 million, reflecting investments in the expansion of life science instruments and laboratory equipment[5] - Long-term deferred expenses decreased by 34.78% to 489,042.87 due to annual amortization of renovation costs[6] - Contract liabilities increased by 219.97% to 3,259,362.80, primarily due to advance payments from foreign customers for orders shipped but not yet recognized as revenue[6] - Total assets decreased from ¥267,787,875.57 at the end of 2023 to ¥260,218,187.84, a decline of about 2.1%[26] - Total liabilities decreased from ¥72,993,083.14 to ¥64,219,102.55, indicating a reduction of approximately 11.9%[25] - The company's equity increased from ¥194,794,792.43 to ¥195,999,085.29, reflecting a growth of about 0.6%[26] Research and Development - Research and development expenses for the first nine months of 2024 were ¥4,685,125.05, compared to ¥5,258,696.12 in the same period of 2023, showing a decrease of approximately 10.9%[27] - Research and development expenses for the current period are 4,685,125.05, down from 5,258,696.12, reflecting a decrease of about 10.9%[29] Other Financial Metrics - Investment income rose by 215.91% to 1,142,545.97, driven by increased interest income from cash management of idle funds[6] - Financial expenses increased by 96.30% to -15,529.08, mainly due to higher loan interest payments[6] - Deferred tax liabilities surged by 1,081.72% to 289,714.83, resulting from temporary taxable differences related to the recognition of right-of-use assets[6] - Non-recurring gains and losses totaled 1,336,356.09, with a tax impact of 200,453.41, resulting in a net amount of 1,135,902.68[7] - The company reported a credit impairment loss of -984,227.81, compared to -1,111,828.90 in the previous year, showing an improvement[29] - The company achieved other income of 3,048,564.68, compared to 3,862,996.82 in the same period last year, indicating a decrease of approximately 21.1%[29] - The total profit before tax is 10,851,962.82, down from 19,169,417.66, representing a decline of about 43.5%[29] Corporate Governance - The company appointed a new board of directors and management team on October 17, 2024, indicating a strategic leadership change[19] - The total number of ordinary shareholders was 1,956 at the end of the reporting period[10] - The total share capital remained at 43,333,100 shares, with no changes during the reporting period[9] - The company has provided guarantees totaling 10,000,000.00 CNY for bank loans, with a guarantee balance of 10,000,000.00 CNY as of the reporting date[17] - The company signed a working capital loan agreement for 10,000,000.00 CNY with a maturity date of November 27, 2024, secured by intellectual property pledges[18] - The company has no new commitments during the reporting period, with previously disclosed commitments available on the designated information disclosure platform[17] - The company has no litigation or arbitration matters during the reporting period[13] - The company has no external guarantees or loans provided during the reporting period[13] - The company reported no significant related party transactions that were not executed in accordance with internal procedures[13] - The company has fulfilled its disclosure obligations regarding significant related party transactions in a timely manner[13] - The company has no significant asset seizures, freezes, or pledges affecting its financial position[18]
博迅生物(836504) - 2024 Q3 - 季度财报